Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL

Bằng Barr, Paul M., Saylors, Gene B., Spurgeon, Stephen E., Cheson, Bruce D., Greenwald, Daniel R., O’Brien, Susan M., Liem, Andre K. D., Mclntyre, Rosemary E., Joshi, Adarsh, Abella-Dominicis, Esteban, Hawkins, Michael J., Reddy, Anita, Di Paolo, Julie, Lee, Hank, He, Joyce, Hu, Jing, Dreiling, Lyndah K., Friedberg, Jonathan W.
Xuất bản năm Blood (2016)

Idelalisib or Placebo in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL - Interim Results of a Phase 3 Randomized, Double-blind Placebo-Contro...

Bằng Zelenetz, Andrew D., Barrientos, Jacqueline C., Brown, Jennifer R., Coiffier, Bertrand, Delgado, Julio, Egyed, Miklós, Ghia, Paolo, Illés, Árpád, Jurczak, Wojciech, Marlton, Paula, Montillo, Marco, Morschhauser, Franck, Pristupa, Alexander S., Robak, Tadeusz, Sharman, Jeff P., Simpson, David, Smolej, Lukáš, Tausch, Eugen, Adewoye, Adeboye H., Dreiling, Lyndah K., Kim, Yeonhee, Stilgenbauer, Stephan, Hillmen, Peter
Xuất bản năm Lancet Oncol (2017)

Risk Model for Overall Survival in Relapsed or Refractory Chronic Lymphocytic Leukaemia in the Era of Targeted Therapies

Bằng Soumerai, Jacob D., Ni, Ai, Darif, Mohamed, Londhe, Anil, Xing, Guan, Mun, Yong, Kay, Neil E., Shanafelt, Tait D., Rabe, Kari G., Byrd, John C., Chanan-Khan, Asher A., Furman, Richard R., Hillmen, Peter, Jones, Jeffrey, Seymour, John F., Sharman, Jeffrey P., Ferrante, Lucille, Mobasher, Mehrdad, Stark, Thomas, Reddy, Vijay, Dreiling, Lyndah K., Bhargava, Pankaj, Howes, Angela, James, Danelle F., Zelenetz, Andrew D.
Xuất bản năm Lancet Haematol (2019)